Giant cell tumors of the sacrum: is non-operative treatment effective?
Angioembolisation
Denosumab
Function preservation
Radiotherapy
Spine tumors
Journal
European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
ISSN: 1432-0932
Titre abrégé: Eur Spine J
Pays: Germany
ID NLM: 9301980
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
received:
26
05
2020
accepted:
20
10
2020
pubmed:
28
10
2020
medline:
25
2
2023
entrez:
27
10
2020
Statut:
ppublish
Résumé
Giant cell tumors of sacrum in which surgery could endanger important neural components were treated with short term denosumab, angioembolisation and radiotherapy in different combinations to provide a non-operative function preserving treatment option. Between April 2013 and April 2017, 13 sacral GCTs [proximal extent of disease-S1 (10), S2 (2) and S3 (1)] were treated. Age ranged from 20 to 50 years. One patient had loss of bladder control at presentation. Treatment protocol included short term denosumab, angioembolisation and radiotherapy in different combinations. Patients were evaluated every 10-12 weeks. If disease ceased to progress no further treatment was advised. In case of progress, patient was advised additional denosumab and/or angioembolisation and/or radiotherapy till disease stopped progressing. 10 patients have non-progressive disease and are asymptomatic, 2 have non-progressive disease with occasional pain, 1 patient died. Follow-up duration (since final non-progression of disease) ranged from 15 to 54 months (mean 31 months). Total number of angio embolisation sessions ranged from 0 to 12 (mean = 4), total number of denosumab doses ranged from 5 to 16 (mean = 9). Five patients did not receive any radiotherapy, 5 received 50.4 Gy and one patient each received 50.4 + 30 + 12 Gy, 50.4 + 30 Gy and 50.4 + 12 Gy. The patient with loss of bladder control at presentation recovered. There were no other long-term complications. This study offers a non-surgical management option that provides good mid-term local control while preserving neurological function in these complex lesions.
Identifiants
pubmed: 33106943
doi: 10.1007/s00586-020-06650-x
pii: 10.1007/s00586-020-06650-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2881-2886Informations de copyright
© 2020. Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Sambri A, Medellin MR, Errani C, Campanacci L, Fujiwara T, Donati D, Parry M, Grimer R (2020) Denosumab in giant cell tumour of bone in the pelvis and sacrum: long-term therapy or bone resection? J Orthopaedic Sci 25(3):513–519. https://doi.org/10.1016/j.jos.2019.05.003
doi: 10.1016/j.jos.2019.05.003
Domovitov SV, Chandhanayingyong C, Boland PJ, McKeown DG, Healey JH (2016) Conservative surgery in the treatment of giant cell tumor of the sacrum: 35 years’ experience. J neurosurg Spine 24(2):228–240. https://doi.org/10.3171/2015.4.spine13215
doi: 10.3171/2015.4.spine13215
pubmed: 26516662
Thangaraj R, Grimer RJ, Carter SR, Stirling AJ, Spilsbury J, Spooner D (2010) Giant cell tumour of the sacrum: a suggested algorithm for treatment. Eur spine J 19(7):1189–1194. https://doi.org/10.1007/s00586-009-1270-8
doi: 10.1007/s00586-009-1270-8
pubmed: 20076978
pmcid: 2900020
Patel S, Chiu RG, Rosinski CL, Ansari D, Chaker AN, Nunna RS, Behbahani M, Mehta AI (2020) Incidence, management, and outcomes of spinal giant cell tumor of bone in adult patients: a national cancer database analysis. World Neurosurg. https://doi.org/10.1016/j.wneu.2020.08.135
doi: 10.1016/j.wneu.2020.08.135
pubmed: 33470214
pmcid: 7832520
van der Heijden L, van de Sande MA, van der Geest IC, Schreuder HW, van Royen BJ, Jutte PC, Bramer JA, Öner FC, van Noort-Suijdendorp AP, Kroon HM, Dijkstra PD (2014) Giant cell tumors of the sacrum–a nationwide study on midterm results in 26 patients after intralesional excision. Eur spine J 23(9):1949–1962. https://doi.org/10.1007/s00586-014-3263-5
doi: 10.1007/s00586-014-3263-5
pubmed: 24614982
Chakravarti A, Spiro IJ, Hug EB, Mankin HJ, Efird JT, Suit HD (1999) Megavoltage radiation therapy for axial and inoperable giant-cell tumor of bone. J Bone Joint Surg Am 81(11):1566–1573. https://doi.org/10.2106/00004623-199911000-00008
doi: 10.2106/00004623-199911000-00008
pubmed: 10565648
Leggon RE, Zlotecki R, Reith J, Scarborough MT (2004) Giant cell tumor of the pelvis and sacrum: 17 cases and analysis of the literature. Clin Orthop Relat Res 423:196–207. https://doi.org/10.1097/01.blo.0000128643.38390.07
doi: 10.1097/01.blo.0000128643.38390.07
Lin PP, Guzel VB, Moura MF, Wallace S, Benjamin RS, Weber KL, Morello FA Jr, Gokaslan ZL, Yasko AW (2002) Long-term follow-up of patients with giant cell tumor of the sacrum treated with selective arterial embolization. Cancer 95(6):1317–1325. https://doi.org/10.1002/cncr.10803
doi: 10.1002/cncr.10803
pubmed: 12216101
Hosalkar HS, Jones KJ, King JJ, Lackman RD (2007) Serial arterial embolization for large sacral giant-cell tumors: mid- to long-term results. Spine 32(10):1107–1115. https://doi.org/10.1097/01.brs.0000261558.94247.8d
doi: 10.1097/01.brs.0000261558.94247.8d
pubmed: 17471094
Chawla S, Henshaw R, Seeger L, Choy E, Blay JY, Ferrari S, Kroep J, Grimer R, Reichardt P, Rutkowski P, Schuetze S, Skubitz K, Staddon A, Thomas D, Qian Y, Jacobs I (2013) Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol 14(9):901–908. https://doi.org/10.1016/S1470-2045(13)70277-8
doi: 10.1016/S1470-2045(13)70277-8
pubmed: 23867211
Todd LTJ, Yaszemski MJ, Currier BL, Fuchs B, Kim CW, Sim FH (2002) Bowel and bladder function after major sacral resection. Clin Orthop Relat Res 1976–2007(397):36–39
doi: 10.1097/00003086-200204000-00006
Puri A, Agarwal MG, Shah M, Srinivas CH, Shukla PJ, Shrikhande SV, Jambhekar NA (2009) Decision making in primary sacral tumors. Spine J 9(5):396–403. https://doi.org/10.1016/j.spinee.2008.10.001
doi: 10.1016/j.spinee.2008.10.001
pubmed: 19059810
Matcuk GR, Patel DB, Schein AJ, White EA, Menendez LR (2015) Giant cell tumor: rapid recurrence after cessation of long-term denosumab therapy. Skeletal Radiol 44(7):1027–1031. https://doi.org/10.1007/s00256-015-2117-5
doi: 10.1007/s00256-015-2117-5
pubmed: 25712768
Mak IW, Evaniew N, Popovic S, Tozer R, Ghert M (2014) A translational study of the neoplastic cells of giant cell tumor of bone following neoadjuvant denosumab. J Bone Joint Surg Am 96(15):e127. https://doi.org/10.2106/JBJS.M.01332
doi: 10.2106/JBJS.M.01332
pubmed: 25100780
Palmerini E, Chawla NS, Ferrari S, Sudan M, Picci P, Marchesi E, Leopardi MP, Syed I, Sankhala KK, Parthasarathy P, Mendanha WE, Pierini M, Paioli A, Chawla SP (2017) Denosumab in advanced/unresectable giant-cell tumour of bone (GCTB): for how long? Eur J Cancer 76:118–124. https://doi.org/10.1016/j.ejca.2017.01.028
doi: 10.1016/j.ejca.2017.01.028
pubmed: 28324746
Broehm CJ, Garbrecht EL, Wood J, Bocklage T (2015) Two cases of sarcoma arising in giant cell tumor of bone treated with denosumab. Case reports in medicine 2015:767198. https://doi.org/10.1155/2015/767198
doi: 10.1155/2015/767198
pubmed: 26798348
pmcid: 4700156
Puri A, Gulia A, Hegde P, Verma V, Rekhi B (2019) Neoadjuvant denosumab: its role and results in operable cases of giant cell tumour of bone. Bone Joint J 101(2):170–177
doi: 10.1302/0301-620X.101B2.BJJ-2018-0907.R2
Errani C, Tsukamoto S, Mavrogenis AF (2017) How safe and effective is denosumab for bone giant cell tumour? Int Orthop 41(11):2397–2400. https://doi.org/10.1007/s00264-017-3536-9
doi: 10.1007/s00264-017-3536-9
pubmed: 28646421
Youn SH, Cho KH, Kim J-Y, Ha B, Lim YK, Jeong JH, Lee SH, Yoo H, Gwak H-S, Shin SH, Hong EK, Kim HK, Hong JB (2018) Clinical outcome of proton therapy for patients with chordomas. Radiat Oncol J 36(3):182–191. https://doi.org/10.3857/roj.2018.00164
doi: 10.3857/roj.2018.00164
pubmed: 30309209
pmcid: 6226136